Clinical Trial: SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07670013) titled 'SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study' on March 04.

Brief Summary: This is a multicenter, single-arm, phase II (Simon two-stage) prospective interventional clinical study. The primary objective is to evaluate the efficacy and safety of lucankizumab (SKB264) in combination with golelixir (a KRAS G12C inhibitor) as first-line treatment in patients with KRAS G12C-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Specifically, the primary endpoint is the objective response rate (ORR) assessed by investigators per RECIST 1.1 to verify the core antitumor activity of...